Related Experiment Video
Updated: Aug 10, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
Postsplenectomy sepsis syndrome. How to identify and manage patients at risk
Insights
Postsplenectomy sepsis syndrome, often caused by Pneumococcus, has a high mortality rate. Awareness and pneumococcal vaccination are crucial for asplenic individuals to prevent this severe infection.
Area of Science:
- Infectious Diseases
- Immunology
- Public Health
Background:
- Postsplenectomy sepsis syndrome (PSS) is a rare but life-threatening condition.
- Streptococcus pneumoniae is the most common causative agent in PSS, implicated in over 50% of cases.
- Individuals who have undergone splenectomy, regardless of the reason (e.g., trauma, malignancy), are at risk.
Observation:
- Certain populations, including infants, those with hematologic malignancies, and individuals with compromised humoral immunity, exhibit increased susceptibility to PSS.
- A significant number of asplenic or functionally hyposplenic individuals in the general population remain unaware of their condition and associated risks.
- Even otherwise healthy individuals splenectomized due to trauma can develop PSS.
Findings:
- The mortality rate associated with PSS can exceed 90%.
- Prompt identification of at-risk asplenic or functionally hyposplenic individuals is essential.
- The 23-valent polysaccharide pneumococcal vaccine is recommended for all asplenic or functionally hyposplenic individuals.
Implications:
- Increased public and clinical awareness regarding PSS is necessary to identify at-risk individuals.
- Proactive screening and vaccination strategies are vital for preventing PSS in asplenic populations.
- Healthcare providers must maintain a high index of suspicion for febrile illnesses in asplenic patients, necessitating prompt and thorough investigation.
Abstract:
Established postsplenectomy sepsis syndrome, although infrequent, may carry a mortality rate of over 90%. Pneumococcus (Streptococcus pneumoniae) has been the infective organism in more than 50% of published cases. Certain groups, such as infants, patients with hematologic malignancy, and those with compromised humoral immunity, may be especially susceptible. However, even healthy individuals who have been splenectomized because of trauma may be affected. Within the general population there is a significant pool of asplenic or functionally hyposplenic patients who are not aware of their condition. Efforts must be made to identify any such individual at risk for the postsplenectomy sepsis syndrome. The new 23-valent polysaccharide pneumococcal vaccine should be made available to any asplenic or functionally hyposplenic individual. A high index of suspicion must be maintained for febrile illness in asplenic patients, and if such an illness occurs, a vigorous investigation is mandatory.
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Endocarditis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management

